Economic considerations in designs and modifications of multi-arm, multi-stage adaptive, and adaptive-platform randomised control trials: A systematic literature review

Abstract

ObjectiveThere is uncertainty around whether, and under what circumstances, there is value in embedding economic considerations into multi-arm, multi-stage (MAMS), adaptive, and adaptive-platform trial designs. This systematic review was conducted to assess the analytical methods and factors that are considered when incorporating health economic analyses when designing and modifying MAMS adaptive, and adaptive-platform trials. MethodsThe review searched for health economic analyses, including planned analyses, of interventions assessed through MAMS adaptive, and adaptive-platform trials. The search for articles was conducted in EMBASE, MEDLINE, Web of Science, Scopus, and ClinicalTrials.gov electronic databases from their inception to 7th August 2023. The screening for articles was conducted by two blinded reviewers who followed a predetermined screening process. A narrative synthesis was conducted on the methods used in the analysis and how the results informed the trial designs and modifications. ResultsThe review included 17 articles of which four were results of economic evaluations while 13 were economic evaluation protocols. No trial reported using pre-trial economic evaluations to inform the trial designs. In 14 articles it was possible to estimate the costs and benefits of the interventions at the interim analysis stages. However, there were only five interim cost-effectiveness analyses and three of these informed decisions to drop or maintain trial arms. ConclusionsHealth economics is being embedded in some MAMS adaptive, and platform-adaptive trials to inform trial modifications. However, the use of economic evidence is limited, both by design and circumstance, despite its potential important to adoption decisions.